Seventh Framework Programme and European Commission logos

Advancing the development of life-saving drugs for cardiovascular diseases

Cartardis partner Imabiotech presented poster ‘Multimodal Analysis and Mass Spectrometry Imaging of Atherosclerotic Plaque Tissue’ at the 2016 ASMS meeting

Poster CarTarDis Imabiotech ASMS 2016

Within the CartarDis project we evaluate  several CVD targets  and their mechanism of involvement in the development of CVD is studied with  multimodal molecular imaging techniques. Preliminary data obtained within the CarTarDis project showed that mechanisms related to lipid metabolism and inflammation are genetically and functionally linked to cardiovascular disease (CVD).

As two examples, target PPAP2B (Phosphatidic Acid Phosphatase Type 2B) is associated to lipid phosphatases that hydrolyze and inactivate lysophosphatidic acid (LPA) and the related sphingosine-1- phosphate (S1P). CECR1 (Cat Eye Syndrome Chromosome Region, Candidate 1) regulates the conversion of adenosine into inosine and induces inflammation. As potential key nodes in these mechanisms, we  further investigated the metabolites related to PPAP2B and CECR1 by multimodal molecular imaging.

This first example of combination of ISH, IHC and MSI shows the benefit of multimodal imaging technique for improvement of  the interpretation of biological processes occurring in tissue.  This approach proved to be a promising tool to follow biomarkers of atherosclerotic plaque formation, regression or rupture.

 The results were summarized in a poster and presented at the 2016 ASMS conference in San Antonio, Texas, June 2016